摘要
氯吡格雷是临床常用抗血小板聚集药物,其疗效显著,但存在明显的个体差异。该差异可导致氯吡格雷抗血小板聚集药效下降而引起心血管缺血事件,或使其药效增强而引起出血等不良反应。细胞色素P4502C19*17(CYP2C19*17)基因突变可使代谢酶活性增强,氯吡格雷活性代谢产物暴露增加,使其药效增强。本文系统地综述了近几年国内外CYP2C19*17基因突变与氯吡格雷的疗效关系的研究,为临床个体化用药提供相关参考依据。
Clopidogrel is one of the most commonly used anti -platelet drugs in clinical.But it shows the significant individual differences during effective anti-platelet therapy.The differences induced can′t be effective anti -platelet aggregate that caused cardiovascular ischemic events, or may enhanced the efficacy of clopidogrel and caused bleeding.The study found cytochrome P 450 2 C19＊17 （ CYP2 C19＊17 ） variant can enhance the activity of metabolizing enzymes , increasing the active metabolites exposed to clopidogrel , thereby enhanced the efficacy of clo-pidogrel.This article systematically summarizes domestic and foreign re-searches about the relationship of CYP2C19＊17 variant and the efficacy of clopidogrel in order to provide some suggestions for personalized medi-cine.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2015年第7期577-579,共3页
The Chinese Journal of Clinical Pharmacology
